Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease
Authors:
- 1 December 2003
- journal article
- review article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 33 (1) , 1-7
Abstract
Transfusion-associated graft-versus-host disease (TA-GVHD) is a serious complication of blood component transfusion therapy. Currently, cellular blood components for patients recognized at risk for TA-GVHD are irradiated prior to transfusion in order to prevent this complication. Considerable progress has been made in elucidating the pathophysiology of this highly morbid complication, but questions as to which patients are at risk and what is the most robust technology to prevent TA-GVHD remain. As new technologies for inactivating or modulating leukocyte function are introduced, the question of how to evaluate these technologies becomes relevant. Over the past two decades, a number of research groups have explored technology to inactivate infectious pathogens and leukocytes contaminating cellular blood components. Few clinicians have an in-depth understanding of the methods or the criteria for selection of how to approach new technologies for leukocyte inactivation with potential to replace current methods. This mini review focuses on the salient aspects of current and evolving technology for prevention of TA-GVHD.Keywords
This publication has 47 references indexed in Scilit:
- Inactivation of pathogens in platelet concentrates by using a two‐step procedureVox Sanguinis, 2003
- Fatal graft‐versus‐host disease associated with transfusions of HLA‐ matched, HLA‐homozygous platelets from unrelated donorsTransfusion, 1994
- Transfusion‐associated graft‐versus‐host disease: report of an occurrence following the administration of irradiated bloodTransfusion, 1993
- Prevention of transfusion‐associated graft‐versus‐host disease: selection of an adequate dose of gamma radiationTransfusion, 1993
- Transfusion‐associated graft‐versus‐host disease: do transfusions from second‐degree relatives pose a greater risk than those from first‐ degree relatives?Transfusion, 1992
- A case of transfusion‐associated graft‐versus‐host disease not prevented by white cell‐reduction filtersTransfusion, 1992
- Erythropoietin for the Treatment of Porphyria Cutanea Tarda in a Patient on Long-Term HemodialysisNew England Journal of Medicine, 1990
- Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal PhotochemotherapyNew England Journal of Medicine, 1987
- Practical dosimetric aspects of blood and blood product irradiationTransfusion, 1986
- Immunocompetent Lymphocytes in Previously Frozen Washed Red Cells1Vox Sanguinis, 1974